<DOC>
	<DOCNO>NCT01121562</DOCNO>
	<brief_summary>The purpose study evaluate effect Sunitinib clinical benefit response rate .</brief_summary>
	<brief_title>Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Patients must advance ( unresectable metastatic ) biopsyproven pancreatic NET ( Neuroendocrine Tumor ) Patients poorly differentiate neuroendocrine cancer eligible</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Neuroendocrine tumor</keyword>
</DOC>